FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095627130> ?p ?o ?g. }

• W2095627130 endingPage "1199" @default.
• W2095627130 startingPage "1194" @default.
• W2095627130 abstract "Study objective Airway obstruction (AO) in sarcoidosis is reported to be associated with respiratory symptoms, increased morbidity, and an increased mortality risk. Because AO in sarcoidosis may result from several causes, the therapeutic benefit of corticosteroids is difficult to determine. The aim of this study was to evaluate the therapeutic response of AO attributable to sarcoid granulomas in the bronchial wall. Patients We selected 11 patients who had sarcoidosis with AO (defined as FEV1/vital capacity [VC] < 70%) associated with sarcoid granulomas on an endobronchial biopsy. Exclusion criteria were history of asthma, smoker or exsmoker, stage 4 disease, evidence of extrinsic compression by enlarged lymph nodes, and localized endobronchial stenosis seen during fiberoptic bronchoscopy. Interventions We compared the results of pulmonary function tests and clinical, radiologic, and biological findings at baseline with those obtained at the time of the last pulmonary function tests available, between the sixth and 12th months of treatment. Eight patients took oral corticosteroids (20 to 60 mg/d initially), one received IV methylprednisolone pulses, another took oral hydroxychloroquine, and the last one received IM methotrexate. Measurements and results With treatment, FEV1and FEV1/VC significantly improved in eight patients (72%), normalized in four patients, and was unchanged in the remaining three patients. The mean FEV1 increased from 60.8 ± 10.8% to 76 ± 13.7% of the predicted value (p < 0.02). VC did not change significantly. FEV1/VC increased from 76.1 ± 6.4% to 87.6 ± 10.7% of the predicted value (p < 0.01). Dyspnea on exertion and other clinical findings were attenuated in 10 patients; the chest radiograph improved in 9 patients, and normalized in 5 patients. The mean serum angiotensin-converting enzyme level decreased from 112 ± 48 to 58 ± 40 IU/mL (p < 0.05), and normalized in four patients. Conclusion The present study indicates that AO caused by sarcoid granulomas in the bronchial wall can be either partially or completely reversed by treatment with a concomitant attenuation of pulmonary symptoms. Airway obstruction (AO) in sarcoidosis is reported to be associated with respiratory symptoms, increased morbidity, and an increased mortality risk. Because AO in sarcoidosis may result from several causes, the therapeutic benefit of corticosteroids is difficult to determine. The aim of this study was to evaluate the therapeutic response of AO attributable to sarcoid granulomas in the bronchial wall. We selected 11 patients who had sarcoidosis with AO (defined as FEV1/vital capacity [VC] < 70%) associated with sarcoid granulomas on an endobronchial biopsy. Exclusion criteria were history of asthma, smoker or exsmoker, stage 4 disease, evidence of extrinsic compression by enlarged lymph nodes, and localized endobronchial stenosis seen during fiberoptic bronchoscopy. We compared the results of pulmonary function tests and clinical, radiologic, and biological findings at baseline with those obtained at the time of the last pulmonary function tests available, between the sixth and 12th months of treatment. Eight patients took oral corticosteroids (20 to 60 mg/d initially), one received IV methylprednisolone pulses, another took oral hydroxychloroquine, and the last one received IM methotrexate. With treatment, FEV1and FEV1/VC significantly improved in eight patients (72%), normalized in four patients, and was unchanged in the remaining three patients. The mean FEV1 increased from 60.8 ± 10.8% to 76 ± 13.7% of the predicted value (p < 0.02). VC did not change significantly. FEV1/VC increased from 76.1 ± 6.4% to 87.6 ± 10.7% of the predicted value (p < 0.01). Dyspnea on exertion and other clinical findings were attenuated in 10 patients; the chest radiograph improved in 9 patients, and normalized in 5 patients. The mean serum angiotensin-converting enzyme level decreased from 112 ± 48 to 58 ± 40 IU/mL (p < 0.05), and normalized in four patients. The present study indicates that AO caused by sarcoid granulomas in the bronchial wall can be either partially or completely reversed by treatment with a concomitant attenuation of pulmonary symptoms." @default.
• W2095627130 created "2016-06-24" @default.
• W2095627130 creator A5007812941 @default.
• W2095627130 creator A5029603798 @default.
• W2095627130 creator A5044075773 @default.
• W2095627130 creator A5062131391 @default.
• W2095627130 creator A5068145736 @default.
• W2095627130 creator A5087410914 @default.
• W2095627130 date "1999-11-01" @default.
• W2095627130 modified "2023-10-17" @default.
• W2095627130 title "Airway Obstruction in Bronchial Sarcoidosis" @default.
• W2095627130 cites W1963947075 @default.
• W2095627130 cites W1968250106 @default.
• W2095627130 cites W1969390108 @default.
• W2095627130 cites W1975911917 @default.
• W2095627130 cites W2052182621 @default.
• W2095627130 cites W2053273082 @default.
• W2095627130 cites W2066984795 @default.
• W2095627130 cites W2068030265 @default.
• W2095627130 cites W2073251171 @default.
• W2095627130 cites W2089418479 @default.
• W2095627130 cites W2097751196 @default.
• W2095627130 cites W2128919988 @default.
• W2095627130 cites W2136091685 @default.
• W2095627130 cites W2144190150 @default.
• W2095627130 cites W2152958413 @default.
• W2095627130 cites W2160501836 @default.
• W2095627130 cites W2161056386 @default.
• W2095627130 cites W2170815641 @default.
• W2095627130 cites W4235586515 @default.
• W2095627130 doi "https://doi.org/10.1378/chest.116.5.1194" @default.
• W2095627130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10559075" @default.
• W2095627130 hasPublicationYear "1999" @default.
• W2095627130 type Work @default.
• W2095627130 sameAs 2095627130 @default.
• W2095627130 citedByCount "57" @default.
• W2095627130 countsByYear W20956271302012 @default.
• W2095627130 countsByYear W20956271302013 @default.
• W2095627130 countsByYear W20956271302014 @default.
• W2095627130 countsByYear W20956271302015 @default.
• W2095627130 countsByYear W20956271302016 @default.
• W2095627130 countsByYear W20956271302017 @default.
• W2095627130 countsByYear W20956271302019 @default.
• W2095627130 countsByYear W20956271302021 @default.
• W2095627130 countsByYear W20956271302022 @default.
• W2095627130 crossrefType "journal-article" @default.
• W2095627130 hasAuthorship W2095627130A5007812941 @default.
• W2095627130 hasAuthorship W2095627130A5029603798 @default.
• W2095627130 hasAuthorship W2095627130A5044075773 @default.
• W2095627130 hasAuthorship W2095627130A5062131391 @default.
• W2095627130 hasAuthorship W2095627130A5068145736 @default.
• W2095627130 hasAuthorship W2095627130A5087410914 @default.
• W2095627130 hasConcept C105922876 @default.
• W2095627130 hasConcept C126322002 @default.
• W2095627130 hasConcept C141071460 @default.
• W2095627130 hasConcept C2775934546 @default.
• W2095627130 hasConcept C2776042228 @default.
• W2095627130 hasConcept C2778333281 @default.
• W2095627130 hasConcept C2778996910 @default.
• W2095627130 hasConcept C2781301800 @default.
• W2095627130 hasConcept C71924100 @default.
• W2095627130 hasConcept C75603125 @default.
• W2095627130 hasConcept C90924648 @default.
• W2095627130 hasConceptScore W2095627130C105922876 @default.
• W2095627130 hasConceptScore W2095627130C126322002 @default.
• W2095627130 hasConceptScore W2095627130C141071460 @default.
• W2095627130 hasConceptScore W2095627130C2775934546 @default.
• W2095627130 hasConceptScore W2095627130C2776042228 @default.
• W2095627130 hasConceptScore W2095627130C2778333281 @default.
• W2095627130 hasConceptScore W2095627130C2778996910 @default.
• W2095627130 hasConceptScore W2095627130C2781301800 @default.
• W2095627130 hasConceptScore W2095627130C71924100 @default.
• W2095627130 hasConceptScore W2095627130C75603125 @default.
• W2095627130 hasConceptScore W2095627130C90924648 @default.
• W2095627130 hasIssue "5" @default.
• W2095627130 hasLocation W20956271301 @default.
• W2095627130 hasLocation W20956271302 @default.
• W2095627130 hasOpenAccess W2095627130 @default.
• W2095627130 hasPrimaryLocation W20956271301 @default.
• W2095627130 hasRelatedWork W1745758340 @default.
• W2095627130 hasRelatedWork W1829349162 @default.
• W2095627130 hasRelatedWork W1979703906 @default.
• W2095627130 hasRelatedWork W2090473051 @default.
• W2095627130 hasRelatedWork W2113028538 @default.
• W2095627130 hasRelatedWork W2225249311 @default.
• W2095627130 hasRelatedWork W2404150153 @default.
• W2095627130 hasRelatedWork W2418496916 @default.
• W2095627130 hasRelatedWork W2442950715 @default.
• W2095627130 hasRelatedWork W3029577031 @default.
• W2095627130 hasVolume "116" @default.
• W2095627130 isParatext "false" @default.
• W2095627130 isRetracted "false" @default.
• W2095627130 magId "2095627130" @default.
• W2095627130 workType "article" @default.